Portal de Periódicos da CAPES

Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020

2020; American Medical Association; Volume: 180; Issue: 12 Linguagem: Inglês

10.1001/jamainternmed.2020.4130

2168-6114

Fiona P. Havers, Carrie Reed, Travis Lim, Joel M. Montgomery, John D. Klena, Aron J. Hall, Alicia M. Fry, Deborah Cannon, Cheng‐Feng Chiang, Aridth Gibbons, Inna Krapiunaya, Maria Morales-Betoulle, Katherine Roguski, Mohammad Rasheed, Brandi Freeman, Sandra Lester, Lisa A. Mills, Darin S. Carroll, S. Michele Owen, Jeffrey A. Johnson, Vera Semenova, Carina Blackmore, Debra Blog, Shua J. Chai, Angela Dunn, Julie Hand, Seema Jain, Scott Lindquist, Ruth Lynfield, Scott Pritchard, Theresa Sokol, Lynn Sosa, George Turabelidze, Sharon Watkins, John Wiesman, Randall Williams, Stephanie Yendell, Jarad Schiffer, Natalie J. Thornburg,

COVID-19 Clinical Research Studies

Reported cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection likely underestimate the prevalence of infection in affected communities. Large-scale seroprevalence studies provide better estimates of the proportion of the population previously infected.